Insider Transactions in Q2 2024 at Edwards Lifesciences Corp (EW)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 20
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,625
-7.85%
|
$489,375
$87.79 P/Share
|
|
Jun 20
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,625
+13.45%
|
$253,125
$45.28 P/Share
|
|
Jun 20
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
535
-2.22%
|
$48,150
$90.0 P/Share
|
|
Jun 20
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
535
+2.18%
|
$24,075
$45.28 P/Share
|
|
Jun 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.63%
|
$435,000
$87.54 P/Share
|
|
Jun 12
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.78%
|
$225,000
$45.28 P/Share
|
|
May 30
2024
|
Bernard J Zovighian CEO |
SELL
Open market or private sale
|
Direct |
8,617
-11.22%
|
$749,679
$87.68 P/Share
|
|
May 21
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,625
-15.54%
|
$506,250
$90.45 P/Share
|
|
May 21
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,625
+13.45%
|
$253,125
$45.28 P/Share
|
|
May 11
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,198
-3.77%
|
$103,028
$86.72 P/Share
|
|
May 11
2024
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,854
-3.58%
|
$245,444
$86.72 P/Share
|
|
May 11
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
814
-1.7%
|
$70,004
$86.72 P/Share
|
|
May 11
2024
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
821
-2.61%
|
$70,606
$86.72 P/Share
|
|
May 11
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
21
-0.01%
|
$1,806
$86.72 P/Share
|
|
May 11
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
377
-1.58%
|
$32,422
$86.72 P/Share
|
|
May 11
2024
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
985
-0.44%
|
$84,710
$86.72 P/Share
|
|
May 11
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
827
-1.07%
|
$71,122
$86.72 P/Share
|
|
May 11
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.32%
|
$19,694
$86.72 P/Share
|
|
May 10
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Open market or private sale
|
Direct |
5,000
-9.48%
|
$435,000
$87.81 P/Share
|
|
May 10
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.66%
|
$225,000
$45.28 P/Share
|
|
May 08
2024
|
Leslie C. Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,055
+50.0%
|
-
|
|
May 08
2024
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,054
+34.89%
|
-
|
|
May 08
2024
|
Heisz Leslie Stone Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,055
+9.23%
|
-
|
|
May 08
2024
|
Paul A Laviolette Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,055
+22.09%
|
-
|
|
May 08
2024
|
Ramona Sequeira Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,055
+27.25%
|
-
|
|
May 08
2024
|
Nicholas J Valeriani Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,818
+6.13%
|
-
|
|
May 08
2024
|
Steven R Loranger Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,054
+3.26%
|
-
|
|
May 07
2024
|
Daveen Chopra CVP, TMTT |
SELL
Payment of exercise price or tax liability
|
Direct |
447
-1.4%
|
$37,995
$85.09 P/Share
|
|
May 07
2024
|
Daveen Chopra CVP, TMTT |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+18.02%
|
-
|
|
May 07
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Open market or private sale
|
Direct |
857
-3.46%
|
$72,845
$85.6 P/Share
|
|
May 07
2024
|
Daniel J. Lippis CVP, JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
586
-2.31%
|
$49,810
$85.09 P/Share
|
|
May 07
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Exercise of conversion of derivative security
|
Direct |
857
+3.27%
|
$30,852
$36.75 P/Share
|
|
May 07
2024
|
Daniel J. Lippis CVP, JAPAC |
BUY
Grant, award, or other acquisition
|
Direct |
7,560
+14.18%
|
-
|
|
May 07
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
619
-1.28%
|
$52,615
$85.09 P/Share
|
|
May 07
2024
|
Donald E Bobo Jr CVP,Strategy/Corp Development |
BUY
Grant, award, or other acquisition
|
Direct |
6,700
+12.17%
|
-
|
|
May 07
2024
|
Catherine M. Szyman CVP, Critical Care |
SELL
Payment of exercise price or tax liability
|
Direct |
609
-0.78%
|
$51,765
$85.09 P/Share
|
|
May 07
2024
|
Catherine M. Szyman CVP, Critical Care |
BUY
Grant, award, or other acquisition
|
Direct |
32,025
+29.21%
|
-
|
|
May 07
2024
|
Wayne Markowitz GM & SVP, Surgical |
BUY
Grant, award, or other acquisition
|
Direct |
3,350
+23.93%
|
-
|
|
May 07
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
178
-1.02%
|
$15,130
$85.09 P/Share
|
|
May 07
2024
|
Robert W.A. Sellers SVP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,445
+12.27%
|
-
|
|
May 07
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-2.43%
|
$67,150
$85.09 P/Share
|
|
May 07
2024
|
Scott B. Ullem CVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,075
+25.39%
|
-
|
|
May 07
2024
|
Bernard J Zovighian CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
647
-0.81%
|
$54,995
$85.09 P/Share
|
|
May 07
2024
|
Bernard J Zovighian CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,500
+29.43%
|
-
|
|
May 07
2024
|
Larry L Wood Global President TAVR & Surg |
SELL
Payment of exercise price or tax liability
|
Direct |
695
-0.31%
|
$59,075
$85.09 P/Share
|
|
May 07
2024
|
Larry L Wood Global President TAVR & Surg |
BUY
Grant, award, or other acquisition
|
Direct |
8,725
+3.73%
|
-
|
|
May 07
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-0.02%
|
$3,910
$85.09 P/Share
|
|
May 07
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
BUY
Grant, award, or other acquisition
|
Direct |
7,125
+3.71%
|
-
|
|
May 06
2024
|
Bernard J Zovighian CEO |
BUY
Open market or private purchase
|
Indirect |
580
+15.08%
|
$49,300
$85.74 P/Share
|
|
May 06
2024
|
Jean Luc M Lemercier CVP, EMEACLA and JAPAC |
SELL
Payment of exercise price or tax liability
|
Direct |
259
-0.15%
|
$22,015
$85.25 P/Share
|